Strategic Timing of Antiretroviral Treatment
What is the purpose of this trial?
- To find out if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their cluster-of-differentiation-4 (CD4)+ cell count is still fairly high, instead of waiting until the CD4+ count is at the level where there is good evidence for starting medicines.
- To learn more about how a strategy of starting HIV medicines early might affect other aspects of care, such as the chances of developing other illnesses or resistance to HIV medicines, the frequency of doctor visits, the cost of medical care, and general health and satisfaction.
- 18 Years and older
- National Institute of Allergy and Infectious Diseases (NIAID)
University of Minnesota - Clinical and Translational Science Institute
- March 2009
- Last Updated:
- January 6, 2014
- Study HIC#:
Clinicaltrials.gov ID: NCT00867048